Kim Kelderman - Net Worth and Insider Trading

Kim Kelderman Net Worth

The estimated net worth of Kim Kelderman is at least $0 dollars as of 2024-04-27. Kim Kelderman is the Pres. Diagnostics & Genom of Bio-Techne Corp and owns about 0 shares of Bio-Techne Corp (TECH) stock worth over $0. Details can be seen in Kim Kelderman's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Kim Kelderman has not made any transactions after 2021-11-19 and currently still holds the listed stock(s).

Transaction Summary of Kim Kelderman

To

Kim Kelderman Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Kim Kelderman owns 1 companies in total, including Bio-Techne Corp (TECH) .

Click here to see the complete history of Kim Kelderman’s form 4 insider trades.

Insider Ownership Summary of Kim Kelderman

Ticker Comapny Transaction Date Type of Owner
TECH Bio-Techne Corp 2021-11-19 Pres. Diagnostics & Genom

Kim Kelderman Latest Holdings Summary

Kim Kelderman currently owns a total of 1 stock. Kim Kelderman owns 0 shares of Bio-Techne Corp (TECH) as of November 19, 2021, with a value of $0.

Latest Holdings of Kim Kelderman

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
TECH Bio-Techne Corp 2021-11-19 0 64.06 0

Holding Weightings of Kim Kelderman


Kim Kelderman Form 4 Trading Tracker

According to the SEC Form 4 filings, Kim Kelderman has made a total of 5 transactions in Bio-Techne Corp (TECH) over the past 5 years, including 0 buys and 5 sells. The most-recent trade in Bio-Techne Corp is the sale of 2,000 shares on November 19, 2021, which brought Kim Kelderman around $252,690.

Insider Trading History of Kim Kelderman

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Kim Kelderman Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Kim Kelderman Ownership Network

Ownership Network List of Kim Kelderman

No Data

Ownership Network Relation of Kim Kelderman


Kim Kelderman Owned Company Details

What does Bio-Techne Corp do?

Who are the key executives at Bio-Techne Corp?

Kim Kelderman is the Pres. Diagnostics & Genom of Bio-Techne Corp. Other key executives at Bio-Techne Corp include PRESIDENT & PROTEIN SCIENCES William Geist , director & Chief Executive Officer Charles R. Kummeth , and SVP - General Counsel Shane Bohnen .

Bio-Techne Corp (TECH) Insider Trades Summary

Over the past 18 months, Kim Kelderman made no insider transaction in Bio-Techne Corp (TECH). Other recent insider transactions involving Bio-Techne Corp (TECH) include a net sale of 80,322 shares made by Charles R. Kummeth , a net sale of 19,339 shares made by Roeland Nusse , and a net sale of 8,250 shares made by Brenda S. Furlow .

In summary, during the past 3 months, insiders sold 10,400 shares of Bio-Techne Corp (TECH) in total and bought 0 shares, with a net sale of 10,400 shares. During the past 18 months, 107,911 shares of Bio-Techne Corp (TECH) were sold and 0 shares were bought by its insiders, resulting in a net sale of 107,911 shares.

Bio-Techne Corp (TECH)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Bio-Techne Corp Insider Transactions

No Available Data

Kim Kelderman Mailing Address

Above is the net worth, insider trading, and ownership report for Kim Kelderman. You might contact Kim Kelderman via mailing address: 614 Mckinley Place Ne, Minneapolis Mn 55413.

Discussions on Kim Kelderman

No discussions yet.